Neoatricon (Dopamine Hydrochloride)

Dopamine acts on dopaminergic, β1‑adrenergic and α‑adrenergic receptors in a dose‑dependent manner. Low doses cause renal vasodilation, moderate doses increase heart rate and contractility via β1 stimulation, and high doses produce peripheral vasoconstriction through α activation, collectively raising cardiac output and blood pressure.

The specific infusion rate of Neoatricon is individualized by the treating physician based on the patient’s blood pressure, cardiac output, and clinical response. Dosing is titrated in micrograms per kilogram per minute to achieve target hemodynamic goals.

Safety data for dopamine hydrochloride in pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescriber.

To order Neoatricon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Neoatricon (dopamine) provides both inotropic and vasopressor effects, whereas norepinephrine primarily offers potent vasoconstriction with less direct inotropic activity. Choice between them depends on the clinical scenario: dopamine may be preferred when renal perfusion support is desired, while norepinephrine is often used for pure vasoconstriction in septic shock.

Neoatricon must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Neoatricon is given as an intravenous infusion. The vial is reconstituted with the appropriate diluent, then administered through a calibrated infusion pump. Continuous hemodynamic monitoring is essential while the infusion is titrated to the desired effect.

Serious risks include myocardial ischemia, severe hypertension or hypertensive crisis, life‑threatening arrhythmias, tissue necrosis at the infusion site, pulmonary edema, and anaphylactic reactions. Prompt recognition and intervention are critical if any of these events occur.

Neoatricon should be avoided in patients with known hypersensitivity to dopamine or any excipients, in those with uncontrolled tachyarrhythmias, severe ventricular dysfunction where excessive inotropy could be harmful, and in patients receiving MAO inhibitors without careful supervision.